Portal Instruments is pleased to be showcasing its latest drug delivery platform at the LSI conference in California next week. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact.
Portal Instruments will be showcasing its newest drug delivery platform at the prestigious Life Science Intelligence (LSI) conference in California next week. The company plans to showcase its latest injector platform, representing a significant advancement in reusable injectors. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact on the industry. This appearance at LSI marks an important milestone for Portal as it continues to expand its market presence and forge strategic partnerships within the healthcare ecosystem. Industry experts and potential investors are encouraged to schedule meetings with the Portal team to explore collaboration opportunities and witness firsthand how their innovations are addressing critical challenges in medical delivery systems.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
June 2021 - Needles are a 150-year-old technology. The world around us is rapidly evolving but drug delivery has not made the same technological strides that other medical devices have. Portal Instruments is looking to change that with a highly innovative needle-free drug delivery injector.
September 2021 - Patrick Anquetil sat down with ASAP Biopharma ahead of his keynote "Alliance Managers Are Bringing Digital Health Innovation" which is slated for 10:20 a.m. EDT on September 28th. The keynote will be followed by a Q&A session.
Please fill out the details below and we will get back to you shortly.